Risk-averse investors may want to look elsewhere.
Compare SAVA Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
Cassava Sciences, Inc.
News & Analysis: Cassava Sciences, Inc.
Investors are excited about upcoming presentations scheduled for the annual Alzheimer's Association International Conference.
This small-cap biotech has shot up in value as the company's Alzheimer's drug makes it way through clinical trials.
The stock market is excited by the clinical trial results for its Alzheimer's drug.
The biotech stock bounced back big Monday after tumbling on Friday.
Now the question is whether the gains are here to stay.
Just because the stock has had a massive run doesn't mean its biggest gains are behind it.
Can this biotech underdog develop an Alzheimer's drug investors can count on?
Investors applauded the company's update on its clinical programs.
New approaches to treating Alzheimer's could mean even bigger gains in the future.